@article{a6001ac70c954e588a787fe6bb09dce2,
title = "Postoperative therapy with infliximab for crohn{\textquoteright}s disease: A 2-year prospective randomized multicenter study in japan",
abstract = "Purpose The prevention of postoperative recurrence is a critical issue in surgery for Crohn{\textquoteright}s disease. Prospective randomized trials in Western countries have shown that the postoperative use of anti-tumor necrosis factor α-antibodies was effective in reducing the recurrence rate. We investigated the efficacy of infliximab (IFX) for the prevention of postoperative Crohn{\textquoteright}s disease recurrence. Methods We performed a prospective randomized multicenter study. Patients who underwent intestinal resection were assigned to groups treated with or without IFX. Immediately after surgery, patients in the IFX group received IFX at 5 mg/ kg at 0, 2, and 6 weeks, followed by every 8 weeks for 2 years. The primary study outcome was the proportion of patients with endoscopic and/or clinical recurrence at 2 years after surgery. Results Thirty-eight eligible patients participated in this study: 19 in the IFX group and 19 in the non-IFX group. The disease recurrence rate in the IFX group was 52.6% (10/19), which was significantly lower than that in the non-IFX group (94.7% [18/19]). Conclusion The postoperative use of IFX is effective in preventing Crohn{\textquoteright}s disease recurrence for 2 years.",
keywords = "A prospective randomized multicenter study, Crohn{\textquoteright}s disease, Infliximab, Postoperative recurrence",
author = "Kouhei Fukushima and Akira Sugita and Kitaro Futami and Takahashi, {Ken Ichi} and Satoshi Motoya and Hideaki Kimura and Shusaku Yoshikawa and Yoshitaka Kinouchi and Hideki Iijima and Katsuya Endo and Toshihumi Hibi and Mamoru Watanabe and Iwao Sasaki and Yasuo Suzuki",
note = "Funding Information: The study was supported by a grant from the Intractable Diseases, Health and Labor and Labor Sciences Research Grants from the Ministry of Health, Labor and Welfare of Japan. Members of the study group: In addition to the authors, the other members of the study group were as follows: Takayuki Yamamoto, MD (Inflammatory Bowel Disease Centre & Department of Surgery, Yokkaichi Social Insurance Hospital); Yoshitaka Ueno, MD (Department of Endoscopy, Hiroshima University Hospital); Kaoru Yokoyama, MD (Department of Gastroenterology, Kitasato University School of Medicine); Akihiko Ohta, MD (Ieda Hospital); Masaru Yoshida, MD (Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine,); Michio Itabashi, MD (Department of Surgery, Institute of Gastroenterology, Tokyo Women{\textquoteright}s Medical University); Naoki Tomotsugi, phD (Kanagawa Prefectural Hospital Organization); Yoko Ito, phD (Keio University Hospital, Clinical and Translational Research Center); Toru Takebayashi MD (Department of Preventive Medicine and Public Health, Keio University School of Medicine); Eisuke Inoue, MD (National Center for Child health and Development); Kazuhiro Watanabe, MD, (Department of Surgery, Tohoku University Graduate School of Medicine); and Sho Haneda, MD (Department of Colorectal Surgery, Tohoku Rosai Hos-pital). The institute of each author was as follows: K.F. (Laboratory of Gastrointestinal Tract Reconstruction, Tohoku University Graduate School of Biomedical Engineering), A.S. (Department of Surgery, Yokohama Municipal Hospital), K.F. (Department of Surgery, Chikushi Hospital, School of Medicine Fukuoka University), K.T. (Depart-ment of Colorectal Surgery, Tohoku Rosai Hospital), S.M. (Department of Gastroenterology, Sapporo Kosei Hospital), H.K. (Inflammatory Bowel Disease Center, Yokohama City University Medical Center), S.Y. (Department of Surgery, Kenseikai Dongo Hospital, Coloproctology Center), Y.K. (Center for the Advancement of Higher Education, Tohoku University), H.I. (Department of Gastroenterology and Hepatology Osaka University Graduate School of Medicine), K.E. (Division of Gastroenterology, Tohoku University Graduate School of Medicine), T.H. (Centre for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital), M.W. (Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University), I.S. (Miyagi Kenshin Plaza), and Y.S. (Division of Gastroenterology and Hepatology, Department of Internal Medicine, Toho University Sakura Medical Center). Funding Information: Fig. 3 The CDAI (a) and CRP (b) values at 0, 6, 12, 18, and 24 months. Open circle and triangle, with infliximab; closed circle and triangle, without infliximab; triangle, case of endoscopic recurrence. The bar indicates the mean value of each group. No significant differences in the values were observed between the infliximab and Acknowledgements The study was supported by a grant from the Intractable Diseases, Health and Labor and Labor Sciences Research Grants from the Ministry of Health, Labor and Welfare of Japan. Publisher Copyright: {\textcopyright} Springer Nature Singapore Pte Ltd. 2018.",
year = "2018",
month = jan,
day = "30",
doi = "10.1007/s00595-018-1627-x",
language = "English",
volume = "48",
pages = "584--590",
journal = "Surgery Today",
issn = "0941-1291",
publisher = "Springer Japan",
number = "6",
}